DESTINY-Breast03 Phase 3 Study Results
Antitumor Responses
Best change from baseline
in target lesion size (%)
100.
N=29
50-
0.
-50-
-100-
I
Patients evaluable for
confirmed response"
27
Confirmed ORR, n (%)
20 (74)
95% CI
CR, n (%)
PR, n (%)
54-89
2 (7)
18 (67)
†
Daiichi-Sankyo
◆ Confirmed ORR
was observed in
20/27 (74%)
patients
Data cutoff: November 15, 2021
ESMO BC 2022 #166 Mini Oral
"Had the opportunity to have 2 postbaseline scans.
Dotted lines indicate thresholds for partial response (-30%) and progressive disease (20%).
*If the best percentage change from baseline of target lesions cannot be calculated due to progression, withdrawal, or death, the value is imputed at +20%.
".*" Patients with PD as best overall response. †CR with lymph node disease (CR per RECIST in lymph nodes, is <10mm) | Unconfirmed response.
CR, complete response; ORR, objective response rate; PR, partial response.
76View entire presentation